Thank you! I missed the dialysis study, but I really appreciated that it did something so many QI/QA projects fail to do: determine whether there’s any true clinical benefit after a change.
Still waiting for a POCUS study to show that—has one already? It should, but I’d love to see where and how that’s been demonstrated.
I also liked the IDSA guideline, mainly because it’s another example of well-meaning experts doing excellent work. Their critique of the data—on a relatively small but important question—was particularly sharp.
**IDSA seems to hold the largest societal divide between what guidelines recommend and what actually happens in practice. Too many cases of healthcare-associated pneumonia are still treated broadly in patients coming from assisted-living facilities, rather than shifting toward the hospital-acquired pneumonia classification as recommended.
We’re a nation that can only agree on a couple of things:
1) The Super Bowl is worth watching—whether for the game, the halftime show, or the commercials.
and
2) Vancomycin and Zosyn/cefepime will be given broadly to many sick hospitalized patients.
I have been on the lookout for POCUS studies showing benefit - the physiologic rationale is strong and some of the smaller observational / cohort studies are interesting. I think there was an RCT in Chest that suggested benefit. Let us know if you see any others.
Thank you! I missed the dialysis study, but I really appreciated that it did something so many QI/QA projects fail to do: determine whether there’s any true clinical benefit after a change.
Still waiting for a POCUS study to show that—has one already? It should, but I’d love to see where and how that’s been demonstrated.
I also liked the IDSA guideline, mainly because it’s another example of well-meaning experts doing excellent work. Their critique of the data—on a relatively small but important question—was particularly sharp.
**IDSA seems to hold the largest societal divide between what guidelines recommend and what actually happens in practice. Too many cases of healthcare-associated pneumonia are still treated broadly in patients coming from assisted-living facilities, rather than shifting toward the hospital-acquired pneumonia classification as recommended.
We’re a nation that can only agree on a couple of things:
1) The Super Bowl is worth watching—whether for the game, the halftime show, or the commercials.
and
2) Vancomycin and Zosyn/cefepime will be given broadly to many sick hospitalized patients.
I have been on the lookout for POCUS studies showing benefit - the physiologic rationale is strong and some of the smaller observational / cohort studies are interesting. I think there was an RCT in Chest that suggested benefit. Let us know if you see any others.